Abstract | BACKGROUND:
Psoriatic arthritis is a long-term inflammatory arthropathy occurring in a subgroup of patients with psoriasis. In addition to irreversible bone erosions, joint destruction, and skin manifestations, psoriatic arthritis is associated with numerous comorbid conditions. Over the last 5 years, new treatments emerged; the analysis and comparisons of their additional costs and the added benefits have become increasingly important to optimize the limited resources available. METHODS: A systematic literature review covering PubMed, EMBASE, and the Cochrane Library was performed from May 2012 to October 2017 focusing on the most recent evidence of costs, benefits, and burden of psoriatic arthritis and its treatments. All economic evaluations assessing the burden of patients with psoriatic arthritis and written in English were eligible for inclusion. We also performed an assessment of the quality of the studies. RESULTS: Of the 1652 references found in the literature search, nine cost-effectiveness analyses and 12 cost-of-illness studies were included in the current review. Patients with psoriatic arthritis incur substantially higher direct and indirect costs, as compared with patients with psoriasis without arthritis or patients with other inflammatory diseases. The cost of treatment with biologic therapies is the major predictor of the total cost. However, individuals with psoriatic arthritis are also affected by substantial productivity losses and indirect costs. Biologic therapies are generally cost effective vs. conventional therapies (e.g., synthetic drugs) for treating psoriatic arthritis. CONCLUSIONS:
|
Authors | Lucia Sara D'Angiolella, Paolo Angelo Cortesi, Alessandra Lafranconi, Mariangela Micale, Sveva Mangano, Giancarlo Cesana, Lorenzo Giovanni Mantovani |
Journal | PharmacoEconomics
(Pharmacoeconomics)
Vol. 36
Issue 5
Pg. 567-589
(05 2018)
ISSN: 1179-2027 [Electronic] New Zealand |
PMID | 29441473
(Publication Type: Journal Article, Systematic Review)
|
Chemical References |
|
Topics |
- Antirheumatic Agents
(economics, therapeutic use)
- Arthritis, Psoriatic
(drug therapy, economics)
- Cost of Illness
- Cost-Benefit Analysis
(statistics & numerical data)
- Drug Costs
(statistics & numerical data)
- Humans
|